enGene Therapeutics (ENGN) Preferred Stock Liabilities (2022 - 2023)
enGene Therapeutics (ENGN) posted quarterly Preferred Stock Liabilities of $1.6 million for Q2 2023, little changed quarter-over-quarter from $1.6 million in Q1 2023.
enGene Therapeutics (ENGN) Preferred Stock Liabilities (2022 - 2023) Analysis & Trends
enGene Therapeutics (ENGN) has reported Preferred Stock Liabilities for 2 consecutive years, with $1.6 million the latest figure, recorded in Q2 2023.
- In Q2 2023, Preferred Stock Liabilities changed N/A year-over-year to $1.6 million; the TTM figure through Apr 2023 stood at $1.6 million (changed N/A YoY), while the FY2022 annual figure was $49.7 million, changed N/A from the prior year.
- Preferred Stock Liabilities steadied at $1.6 million in Q2 2023 per ENGN's latest filing, from $1.6 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $49.7 million in Q4 2022 and bottomed at $1.6 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2023 | 1.55 Mn |
| Jan 31, 2023 | 1.55 Mn |
| Oct 31, 2022 | 49.67 Mn |